<<However, for purposes of this table, we have assumed that, after completion of the offering, all of the shares covered by this prospectus will be sold by Lincoln Park.>>
I doubt Cavazzas are selling or shorting. Sigma Tau may be up for sale. It could be worth up to $2 billion. Why would they risk SEC ire over a few million bucks to manipulate RGRX? I don't buy it.
Net PIPE to LPC probably late Fall. The shares are registered and declared effective. Ready to sell to LPC.and immediately ready for LPC to sell. Only question is exactly when and at what price. If Dr. Steven Dunn woudl finish hos physicians sponsored phase 2 in dry eye/GVHD.....that might help. Assuming goon news. It wont be goof if results not good. He started the trial in late Dec.
So did "LPC" puke their shares so far????? A simple yes or no.
If they weren’t ‘puking’, then WTF was??
As to your:
'However, for purposes of this table, we have assumed that, after completion of the offering, all of the shares covered by this prospectus will be sold by Lincoln Park'
I don't think that LPC is going to hold them until they die and then try to take their shares to heaven.
I think they're in it for the money and will sell when it's to their maximum benefit vs your idea of buying and instantly 'puking'.
As to your:
'I doubt Cavazzas are selling or shorting. Sigma Tau may be up for sale. It could be worth up to $2 billion. Why would they risk SEC ire over a few million bucks to manipulate RGRX? I don't buy it.'
Who would gain the most from control if not the largest holder.
'Net PIPE to LPC probably late Fall.'
They could be buying any time and it would seem over a period of time if limited to 200,000 shares per day at this price level. LPC is here for a "reason" and you can bet they'll get some cheap shares.
Keep up the good work at the patent office Sno and by all means enjoy the week end.
It's patents are the key here now. Everyone should be hammering RGRX why they are NOT disclosing fully what they have.....in terms of the issued 2007 patent to the NIH.
The US PAtents are probably more important that ANY trial itself. For instance....say the Phase 2 in dry Eye is seen as a winner, what does RGRX have then? very little.....because no pharma will show any interest in partnering a successful Dry Eye drug because they they can't control it's sale. RGRX could have FABULOUS results in trials for...Heart....eyes....Neuro/MS.....CF.....you name it. but without a US PAtent, you got crap (for the most part).
The only indication that might be able to be marketed WITHOUT a patent, would be those in any Orphan drug Status area.......like EB trial. But it's hard to get any hopes up on that one. It's been too long.
if the 2007 patent granted of TB 4 to the NIH does include ALL the areas I cut and pasted from it (heart. eyes, neuro, external..) Then RGRX is in great shape! if not? Then it's back to the 15 years FIGHT with the Patent Office.....taking average 3-5 YEARS for a review...and then getting "non final rejections"....with filings needing tweeking..then another 3-5 year wait. RGRX will be dead by then.
So if any of you are curious, EMAIL Finkelstein. It is veyr material information - just what the 2007 NIH patent encompasses with TB 4. It is wrong that RGRX hides it.....what IS included in detail.